Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Correlogic Systems; NanoString Technologies; Covance; Becton Dickinson; Lab901

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Correlogic Systems this week said that it has fulfilled European Union regulatory requirements to CE Mark its OvaCheck test for epithelial ovarian cancer. The test is a multiplex assay that measures the relative ratios of eight proteins. The Germantwon, Md.-based firm said that it is currently in discussions with potential partners for distribution of OvaCheck in Europe.


NanoString Technologies has launched an early-access program for its nCounter Custom Copy Number Variation Assays for highly multiplexed, direct-digital detection, and counting of CNVs in a single reaction. The firm expects to commercially launch the CNV assays later this year.


Covance this week said that it has opened a new, 20,000-square-foot biorepository to hold its plasma, serum, whole-blood, DNA, PBMC, and tissue samples. The new facility is adjacent to Covance's Biomarker Center of Excellence in Greenfield, Ind.


Becton Dickinson has signed agreements this week to sell certain assets of its BD Medical segment, including its ophthalmic systems unit and the surgical blades, critical care, and extended dwell catheter product platforms of its medical surgical systems unit. Private equity firm RoundTable Healthcare Partners and two of its portfolio companies, Argon Medical Devices and Aspen Surgical Products, are buying the BD assets for an undisclosed sum. BD said the businesses would bring in estimated revenues of $200 million for fiscal-year 2010.


Lab901 has received IS O9001:2008 accreditation for manufacturing quality covering its ScreenTape System for automated gel electrophoresis.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.